DCTH Stock Analysis: Delcath Systems | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 464m USD | 12M Return: 3.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.90M
Qual. Beats: 0
Rev. Trend: 95.7%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Delcath Systems is a small-cap, US-based interventional oncology company focused on treating primary and metastatic liver cancers in the United States and Europe. Its core technology is a hepatic delivery system designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure. The company was founded in 1988 and is headquartered in Queensbury, New York.
The companys lead product candidate is HEPZATO KIT, a melphalan-based hepatic delivery system, supported by the FOCUS clinical trial examining objective response rate in patients with metastatic hepatic-dominant uveal melanoma, a rare eye cancer with a strong tendency to spread to the liver. Delcath also sells its delivery system in Europe under the CHEMOSAT trade name as a stand-alone medical device, allowing medical centers to use it with melphalan to treat a range of liver cancers.
- HEPZATO commercial uptake drives US liver cancer treatment revenue
- European CHEMOSAT sales expand across oncology treatment centers
- Capital raise dilution risk as commercialization cash burn accelerates
| Net Income: 561k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 24.06 > 1.0 |
| NWC/Revenue: 121.2% < 20% (prev 146.8%; Δ -25.67% < -1%) |
| CFO/TA 0.17 > 3% & CFO 21.2m > Net Income 561k |
| Net Debt (-88.4m) to EBITDA (1.67m): -52.99 < 3 |
| Current Ratio: 11.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.0m) vs 12m ago -8.83% < -2% |
| Gross Margin: 85.97% > 18% (prev 84.90%; Δ 1.07% > 0.5%) |
| Asset Turnover: 85.26% > 50% (prev 61.67%; Δ 23.59% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 120.3m - Total Current Liabilities 10.7m) / Total Assets 124.8m |
| B: -4.24 (Retained Earnings -529.9m / Total Assets 124.8m) |
| C: 0.01 (EBIT TTM 1.34m / Avg Total Assets 106.1m) |
| D: 9.29 (Book Value of Equity 112.7m / Total Liabilities 12.1m) |
| Altman-Z'' = 1.76 = BBB |
As of July 11, 2026, the stock is trading at USD 13.01 with a total of 283,567 shares traded. Over the past week, the price has changed by -1.44%, over one month by +16.26%, over three months by +29.58% and over the past year by +3.67%.
Current recommended Stop Loss: 11.60 (which is 10.8% or 2.5 ATR below the current price).
Delcath Systems has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy DCTH.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.4 | 64.1% |
P/E Trailing = 1344.0
P/E Forward = 25.7732
P/S = 5.1301
P/B = 4.043
P/EG = 1.5966
Revenue TTM = 90.4m USD
EBIT TTM = 1.34m USD
EBITDA TTM = 1.67m USD
Long Term Debt = 815k USD (estimated: total debt 907k - short term 92.0k)
Short Term Debt = 92.0k USD (from shortTermDebt, last quarter)
Debt = 907k USD (from shortLongTermDebtTotal, last quarter) (leases 907k already included)
Net Debt = -88.4m USD (calculated: Debt 907k - CCE 89.3m)
Enterprise Value = 375.6m USD (464.0m + Debt 907k - CCE 89.3m)
Interest Coverage Ratio = unknown (Ebit TTM 1.34m / Interest Expense TTM 0.0)
EV/FCF = 19.57x (Enterprise Value 375.6m / FCF TTM 19.2m)
FCF Yield = 5.11% (FCF TTM 19.2m / Enterprise Value 375.6m)
FCF Margin = 21.22% (FCF TTM 19.2m / Revenue TTM 90.4m)
Net Margin = 0.62% (Net Income TTM 561k / Revenue TTM 90.4m)
Gross Margin = 85.97% ((Revenue TTM 90.4m - Cost of Revenue TTM 12.7m) / Revenue TTM)
Gross Margin QoQ = 85.05% (prev 85.48%)
Tobins Q-Ratio = 3.01 (Enterprise Value 375.6m / Total Assets 124.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 907k)
Taxrate = 23.08% (810k / 3.51m)
NOPAT = 1.03m (EBIT 1.34m * (1 - 23.08%))
Current Ratio = 11.24 (Total Current Assets 120.3m / Total Current Liabilities 10.7m)
Debt / Equity = 0.01 (Debt 907k / totalStockholderEquity, last quarter 112.7m)
Debt / EBITDA = -52.99 (Net Debt -88.4m / EBITDA 1.67m)
Debt / FCF = -4.61 (Net Debt -88.4m / FCF TTM 19.2m)
Total Stockholder Equity = 110.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.53% (Net Income 561k / Total Assets 124.8m)
RoE = 0.51% (Net Income TTM 561k / Total Stockholder Equity 110.9m)
RoCE = 1.20% (EBIT 1.34m / Capital Employed (Equity 110.9m + L.T.Debt 815k))
RoIC = 0.94% (NOPAT 1.03m / Invested Capital 109.7m)
WACC = 10.25% (E(464.0m)/V(464.9m) * Re(10.27%) + D(907k)/V(464.9m) * Rd(0.0%) * (1-Tc(0.23)))
Discount Rate = 10.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.44 | Cagr: 22.13%
[DCF] Terminal Value 69.07% ; FCFF base≈19.2m ; Y1≈19.3m ; Y5≈20.4m
[DCF] Fair Price = 9.51 (EV 240.0m - Net Debt -88.4m = Equity 328.4m / Shares 34.5m; r=10.25% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.54 | # QB: 0
Revenue Correlation: 95.69 | Revenue CAGR: 407.6% | SUE: 0.04 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=+6.91% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.21 | Chg30d=+3.94% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.60 | Chg30d=+4.57% | Revisions=-62% | GrowthEPS=-856.2% | GrowthRev=+21.1%
EPS next Year (2027-12-31): EPS=-0.51 | Chg30d=-12.83% | Revisions=-57% | GrowthEPS=+15.7% | GrowthRev=+26.5%
[Analyst] Revisions Ratio: -83% (up=0, down=15)